Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 38662775.
- Also identified by DOI 10.1371/journal.pmed.1004381 and PMC identifier 11081489.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.
Medical subject headings
- Intellectual Property
- Biosimilar Pharmaceuticals